Early Registration Is Open for #ISLB25! Register by October 10, 2025, to take advantage of discounted rates. Full In-Person Registration Includes access to all Scientific Sessions (except ticketed sessions), entry to the Exhibition Hall, and more! Register now at 2025.islb.info/lrdo

🩸🚀 New Insights in Liquid Biopsy! 🧬 The ISLB has just published a perspective article about Minimal requirement for ctDNA analysis. 🔗 Read the full article here www.journalofliquidbiopsy.com/article/S295...

🚨Excited to represent the @islb.info at #ASCO25! Swing by our booth, we’re ready to talk about #LiquidBiopsy and opportunities! Got questions about the society? We’ve got answers. Come to connect!🩸 @ascocancer.bsky.social @christianrolfo.bsky.social @rolfolab.bsky.social

Very honored of this important recognition in my born country. Blessed to share this special moment with my family, friends and great colleagues from Argentina 🇦🇷 looking forward to continue working with @UBAonline from OSU @OhioStateMedOnc ! Thanks to all my team @rolfolab.bsky.social

New research from the #VISION trial of #tepotinib in #NSCLC with #METex14 skipping highlights key differences when patients are identified by LBxvs TBx. ➡️ #Tepotinib showed robust efficacy regardless of biopsy type @christianrolfo.bsky.social @oncoalert.bsky.social

Visit at #AACR25 the poster by Dr. Eswar Shankar on “Synergistic Inhibition of TNBC via EZH2 inhibition and D1 Receptor Agonism” @OSUCCC_James @osuwexmed.bsky.social @christianrolfo.bsky.social @theaacr.bsky.social pbs.twimg.com/media/Gpay9i...

Super excited to share the review I wrote with Carolina Reduzzi published in the Journal of Liquid Biopsy on the transformative impact of LB in oncology! 🩸🔬 LB is reshaping cancer care 💥 Check it out 👉 pubmed.ncbi.nlm.nih.gov/40255897/ @islb.info @christianrolfo.bsky.social @rolfolab.bsky.social

Congrats Roberto! And welcome to @rolfolab.bsky.social !!!

Day 3 at #TexasLung25 diving into diagnostics, #MRD, and #LiquidBiopsy with an outstanding faculty! 🩸🔬 Learning from the best: @christianrolfo.bsky.social @davidgandera @WadeIams @osucccjames.bsky.social @rolfolab.bsky.social Exciting discussions shaping the future of #lungcancer testing! 📚

Honored to be here at hashtag #TexasLung25 in #Austin as one of the 10 winners of the poster competition 🏅 Grateful for the chance to meet with exceptional people 👐 @stephenvliu.bsky.social @tinacascone @christianrolfo.bsky.social

Navigating the future of #LiquidBiopsy with @christianrolfo.bsky.social at #poles25 From screening to resistance tracking—MRD is reshaping how we detect, treat, and monitor cancer. Tissue vs liquid? It’s not a battle—it’s a partnership. @rolfolab.bsky.social @islb.info @oncoalert.bsky.social

As always, an insightful presentation by @UmbertoMalapelle ➡️ "From single gene testing to CGP." 🔬✨ at #ELCC25 @myesmo.bsky.social We must continue this path to improve treatment selection! @islb.info #precisiononcology #lungcancer ⬇️ Key message

Today, I had the pleasure of presenting to the @MtSinaiASCOOSIG on the role of #liquidbiopsy in clinical practice and #precisiononcology! ❤️ An incredibly dynamic and engaging group! Great discussions and insights! @osucccjames.bsky.social @rolfolab.bsky.social @christianrolfo.bsky.social @unige

📢 Exciting update in the field of liquid biopsy! A new editorial highlights the essential role of the International Society of Liquid Biopsy (ISLB) in establishing quality framework for LB clinical implementation. 🧬🩸 Read more: doi.org/10.1016/j.crit…#LiquidBiopsysy @christianrolfo.bsky.social

🚨 Out in @natrevclinoncol.bsky.social 📌ctDNA helps uncover resistance mechanisms 📌Standardized protocols are crucial for improving applications 📌ctDNA + tissue provides a more comprehensive view nature.com/articles/s41... @christianrolfo.bsky.social @osucccjames.bsky.social

Don’t miss this chance to contribute!

Great opportunity to gain valuable insights into METex14 skipping NSCLC! 🎦

Congratulations Roberto! Well deserved! @osucccjames.bsky.social

The HER2 protein is becoming a crucial target not only in breast cancer but also in other tumor subtypes. 🔬✨ Super experts discuss the role of IHC in #lungcancer and #ovariancancer! @christianrolfo.bsky.social @rolfolab.bsky.social @osucccjames.bsky.social #HER2 #IHC #Targettherapy

✨ Insightful presentation by @manelesteller.bsky.social from @carrerasijc.bsky.social at @osuwexmed.bsky.social Starting from #epigenetics to #spatialtranscriptomics, unlocking a deeper understanding of tumor biology and cancer treatment! 🔬🧬💊 @christianrolfo.bsky.social @rolfolab.bsky.social

⏱️ To-do list for today: Tune in to the live webinar by @iaslc.bsky.social covering key highlights from the 2024 Hot Topic in Basic & Translational Science Conference! 🔬🧬 Don't miss out on the latest breakthroughs! @christianrolfo.bsky.social @rolfolab.bsky.social www.iaslc.org/meetings-web...

Amazing group of medical oncologists that I am privileged to work with every day and call friends @stoverlab.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @quirogad.bsky.social @osucccjames.bsky.social

Don't miss the chance to dive into this interesting discussion on lung cancer with an incredible faculty! 🔎🫁💊 #lungcancer #myESMO #DeepDiveLungCancer @christianrolfo.bsky.social @rolfolab.bsky.social ow.ly/vbSt50UPrrS

🎯 The ISLB created this survey to understand how to improve the use of #liquidbiopsy in clinical oncology! Don't miss the opportunity to shape the future of LB in cancer patients!! 🔥 @christianrolfo.bsky.social @robertoboreamd.bsky.social

🚨 Share your expertise in the liquid biopsy field! 🌟 Participate in the #ISLB survey to help shape strategies for improving #liquidbiopsies in clinical oncology. Let’s advance precision care for medical oncologists together! 🩺🔬 @christianrolfo.bsky.social @rolfolab.bsky.social

When tissue is the issue! Great presentation by @christianrolfo.bsky.social at the XIII Molecular Cytopathology We need to use liquid biopsy 🩸 and tissue together to get as many informations as possible! 🧬 @ohiostateuniversity @rolfolab.bsky.social @UmbertoMalapel1 @MariantoniaNac1

🚨Our paper is online at @JTOonline “Efficacy and Safety of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting Transforming Growth Factor-β and Programmed Death-Ligand 1, Plus Chemotherapy in Patients With Stage IV NSCLC”. www.jtocrr.org/action/showP...

Honored to had the opportunity to present my experience on CAR-T cells that I did at @unclineberger.bsky.social at a seminar for PhD students at @Dipsanita_UniNa 💪 Such a great class! @UniGe @UmbertoMalapel1 @christianrolfo.bsky.social @christianrolfo.bsky.social

Amazing #ISLB24 congress in summary: 303 participants, 24 countries 🌎 100 abstracts 📝 50 speakers 👨‍🏫👩‍🏫 26 travel awards ✈️ 3 ISLB awards🥇 32 sponsors 5 satellite symposium ✏️ THAKS ALL OF YOU “THE” INTERNATIONAL LIQUID BIOPSY SOCIETY IS GROWING EVERY YEAR ! @isliquidbiopsy

🌟 A growing society, a brighter future! 📍 Denver welcomed 303 delegates from 24 countries, 100 abstracts, and 76 posters at #ISLB24. See you in Orlando for #ISLB25! #LiquidBiopsy #Oncology #PrecisionMedicine @christianrolfo.bsky.social @rolfolab.bsky.social @oncoalert.bsky.social

Congratulations to Giovanni Nigita who recently joined our lab! we are more than excited to work with him! His expertise in bioinformatics analysis is a key aspect for step up our research level! 🖥️💪🏻 @christianrolfo.bsky.social @osucccjames.bsky.social

Liquid biopsy: a promising tool for cancer screening, but sensitivity for early-stage detection remains a challenge. Innovation is key to improving outcomes. @christianrolfo.bsky.social @rolfolab.bsky.social @oncoalert.bsky.social

Mark your calendars! 🌟 See you at ISLB 2025 in Orlando, USA, from November 1-3. Let’s shape the future of liquid biopsy together. @christianrolfo.bsky.social @rolfolab.bsky.social @oncoalert.bsky.social

Everything started with a single cell, and now it’s time to return to the cell. The evolution of biopsies: from tissue to liquid to cell biopsies. The future is here. @christianrolfo.bsky.social @rolfolab.bsky.social @oncoalert.bsky.social

Excellent slide highlighting two strategies for ctDNA analysis: Tumor-naive for genotyping/screening and Tumor-informed for MRD and response assessment. Precision oncology in action! @christianrolfo.bsky.social @rolfolab.bsky.social @oncoalert.bsky.social

Great panel discussion on the session about early cancer detection at #ISLB24 So many options and ideas for cancer research! 🎯🔍 @christianrolfo.bsky.social #JacobBerchuck #trevorPugh #martaDuenas @internationalsocietyofliquidbiopsy

@christianrolfo.bsky.social presenting at #ISLB24 early detection strategies for different cancers! 📚Many studies are being published in this topic What is the best strategy? —>a mix of different technologies 👨🏻‍🔬👩‍🔬 + AI integration! 🤖 @isliquidbiopsy @OSUCCC_James

Second day at #ISLB24 with @christianrolfo.bsky.social presenting data on early cancer detection in different cancer types! —> is possible but there are many different LB 🩸 method that must be integrated with AI 🤖 @internationalsocietyofliquidbiopsy @ohiostatepress.bsky.social

❔❓Having expert to discuss key questions in liquid biopsy! This is #ISLB24 @isliquidbiopsy @christianrolfo.bsky.social #abhijitPatel #pazVellanki #murryWynes #davidkozono #lucaQuagliata #adamSowalsky

LB - Tissue Detection of gene copy number (CN) losses (PTEN, BRCA1/2, PALB2) in prostate, breast and ovarian cancer. --> High concordance (liquid/tissue) in samples with Tumor Fraction ≥ 20% (sensitivity 83%) #ISLB24 @christianrolfo.bsky.social @internationalsocietyofliquidbiopsy

Wish that I could be at ISLB!! Visionary liquid biopsy expert @christianrolfo.bsky.social gives master class lectures on translational potential for innovative LB technologies & approaches 💯💯 @osucccjames.bsky.social @osuwexmed.bsky.social

Super poster session! 🧨 @UmbertoMalapel1 shows us how an algorithm can filter out genomic alterations while analyzing LB sample in a prostate cancer cohort of patients! #ISLB24 @isliquidbiopsyhttps://x.com/RobertoBoreaMD/status/1860412702520205367/photo/1

At #ISLB24 release of the new @oncoindx multiomics machine on Live Single CTCs combining genomic profiling with CTC DNA and ctDNA 🧬 @christianrolfo.bsky.social

Brilliant presentation by @christianrolfo.bsky.social from OSUCCC on ctDNA fragmentation in solid tumors! 🔑 message ctDNA fragmentation is emerging as a new tool to better understand and use LB in the management of cancer patients! @umbertomalapelle1 @stoverlab.bsky.social

Great presentation from @natashaleighl from @pmargaretcancercenter on the usage of molecular testing in cancer patients! 🥵 Hot topics: - timing ⏱️ - patient point of view 🫵 - type of test 🤷🏻‍♀️ - cost 💰 #ISLB24

Liquid biopsies improve testing rates, reduce delays, and guide optimal treatment in advanced lung cancer. Making it routine is the next big step. #ISLB24 #LiquidBiopsy #Oncology @christianrolfo.bsky.social @rolfolab.bsky.social @oncoalert.bsky.social

LB 🩸 isn’t only for medical oncologist! @aadel_chaudhuri from @MayoClinic is sharing data on the use of LB MRD during and after radiotherapy treatment with great results in predicting patient outcome! #ISLB24 @christianrolfo.bsky.social @rolfolab.bsky.social @isliquidbiopsy

We are all genetic mosaics! Clonal mosaicism is the rule, not the exception. A fascinating insight into our cellular diversity at #ISLB24. #LiquidBiopsy #Oncology @christianrolfo.bsky.social @rolfolab.bsky.social @oncoalert.bsky.social

Nice to meet great international colleagues/researchers at #ISLB24! 🌎 Ready for this great event to share knowledge about liquid biopsy! 🔥 @internationalsocietyofnliquidbiopsy @christianrolfo.bsky.social @umbertomalapelle @brunapellini @robertoboreamd.bsky.social @mariantonianacchio